Floatz logo

VIPIVOTIDE TETRAXETAN

Adenoid Cystic Carcinoma

Maria Sklodowska-Curie National Research Institute of OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Adenoid Cystic Carcinoma cohort.

Asset / SponsorPhaseRating
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Irinotecan
National Cancer Institute (NCI)
Phase 1/2B
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Everolimus
Emory University
Phase 1CCC

View all 28 →

Same molecule, other indications

VIPIVOTIDE TETRAXETAN is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
67 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →